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a  b  s  t  r  a  c  t
We  conducted  a  phase  I, double-blind,  placebo-controlled  trial  to evaluate  a  new  5-valent  oral  rotavirus
vaccine’s  safety  and  immunogenicity  proﬁles.  Subjects  were  randomly  assigned  to  receive  3 orally  admin-
istered doses  of  a live-attenuated  human-bovine  (UK)  reassortant  rotavirus  vaccine,  containing  ﬁve  viral
antigens (G1,  G2, G3,  G4  and  G9),  or a placebo.  The  frequency  and  severity  of  adverse  events  were  assessed.
Immunogenicity  was  evaluated  by  the titers  of anti-rotavirus  IgA  and  the  presence  of neutralizing  anti-eywords:
otavirus
accine
linical trial
afety
mmunogenicity
bodies anti-rotavirus.  No  severe  adverse  events  were  observed.  There  was  no  difference  in  the  frequency
of mild  adverse  events  between  experimental  and  control  groups.  The  proportion  of  seroconversion  was
consistently  higher  in  the  vaccine  group,  for  all serotypes,  after  each  one  of the  doses.  The  5-valent  vac-
cine has  shown  a good  proﬁle  of safety  and  immunogenicity  in  this  small  sample  of  adult  volunteers.
© 2012 Elsevier Ltd. Open access under the Elsevier OA license.. Introduction
New generation rotavirus vaccines were licensed in the
eginning of 2006 [1].  Since then, both Merck’s pentavalent human-
ovine reassortant vaccine (RotaTeq®) and GSK’s monovalent
ttenuated human vaccine (Rotarix®) have been widely used. Sev-
ral studies have shown a reduction in rotaviral gastroenteritis
r diarrhea incidence and mortality following vaccine introduc-
ion [2–4]. In 2009, the World Health Organization recommended
he introduction of rotavirus vaccines into national immunization
rograms for controlling rotavirus gastroenteritis [5].  However,
accines prices still represent a hurdle in the expansion of their
se [6,7].
The Instituto Butantan, one of the Brazilian public vaccine man-
facturers, is participating in an international effort to develop a
ew rotavirus vaccine. An agreement between Path Foundation and
nstituto Butantan has made possible the technology transfer for
he production of the UK-based reassortant tetravalent rotavirus
accine, with ﬁnancial support from the Bill & Melinda Gates
∗ Corresponding author.
E-mail addresses: eluna@usp.br, expedito luna@uol.com.br (E.J.A. Luna).
264-410X     ©  2012 Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.vaccine.2012.12.020
Open access under the Elsevier OA license.Foundation. The Instituto Butantan has added an additional
serotype to the vaccine, G9, as this is one of the most prevalent in
Brazil [8].  It is expected that this new vaccine, that includes the most
frequent serotypes found in Brazil, will contribute to the reduc-
tion of the burden of rotavirus disease in Brazil and elsewhere, at
a reduced cost. Being a public, not for proﬁt vaccine manufacturer,
Butantan considers its mission to produce immunobiologicals for
the Brazilian National Immunization Program at lower prices than
the market.
Brazil introduced the monovalent attenuated human rotavirus
vaccine (Rotarix®) in its universal vaccination program in 2007.
Vaccine coverage has been above 80% in all years since the introduc-
tion (CM Domingues, head of the Brazilian National Immunization
Program, personal communication). The persistence of detection
of some rotavirus genotypes among Brazilian infants, such as G2P
[4], suggests that the vaccine currently in use might be less efﬁca-
cious against certain rotavirus serotypes [9–11]. This would be an
additional reason for the development of new vaccines.
In 1999, the ﬁrst rotavirus vaccine was withdrawn from the mar-
ket because of an increased risk of intussusception among vaccine
recipients. As a result, the new generation vaccines were evaluated
in trials with large sample sizes powered to detect an increased
risk for intussusception, which was  not observed [11–13].  Recent
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nalysis conducted after the extensive use of these vaccines in Latin
merica pointed to a slightly increased risk of intussusception, but
he authors concluded that the number of deaths and hospitaliza-
ions averted because of vaccination far exceeded the number of
ntussusception cases associated with the vaccine [14].
This paper presents the results of a phase I clinical trial of a
ew 5-valent rotavirus vaccine. The primary objective of the study
as to assess the vaccine’s safety. The secondary objective was to
valuate its immunogenicity.
. Methods
.1. Study design
This was a phase I, randomized, double blind clinical trial. Volun-
eers were randomly allocated to either the experimental or control
roup. Those in the experimental group received three doses of the
andidate vaccine, and those in the control group three doses of
lacebo. The study’s protocol was approved by the ethics review
oard of Hospital das Clínicas, of the University of São Paulo (USP),
y the Brazilian National Health Regulatory Authority (ANVISA),
nd was registered at ClinicalTrials.gov (NTC 00981669). The study
as conducted in accordance with the principles of the Declara-
ion of Helsinki and in compliance with Good Clinical Practices
uidelines.
In their ﬁrst visit to the Clinical Research Unit of ICr-HC-FMUSP,
olunteers had an eligibility interview. The Informed Consent Form
as presented, discussed and signed. Medical history and a phys-
cal examination were carried out. Blood and urine samples were
ollected and sent immediately to the laboratory of the ICr-HC-
MUSP. A blood sample of 10 ml  was drawn to be used for the
ollowing tests: blood cell counts, glucose, liver and kidney func-
ion tests and HIV serology. In their second medical appointment,
he eligibility lab tests were evaluated. If any of the tests presented
bnormal results, the candidate would not be enrolled. Instead he
as referred to the appropriate outpatient service for clinical diag-
osis and follow up.
Volunteers were allocated to either the experimental or control
roup following a blocked design with block size of four. The use of
 blocked allocation design assures uniform numbers of volunteers
n the study groups.
Randomized volunteers received 3 orally administered doses of
accine or placebo, at intervals of between 6 and 8 weeks. Before
eceiving the ﬁrst dose, volunteers had a rotavirus serology test-
ng (1st evaluation). After vaccination, volunteers remained under
edical observation for 2 h. They were released after that, provided
o adverse event was observed. Medical assistance was available
n site, if needed. On the same day, the volunteer received a partici-
ant’s diary and a container for feces collection. The diary contained
ll necessary information about the protocol. The volunteer would
lso ﬁnd in the diary all his scheduled appointments for medi-
al evaluations, vaccinations and lab sample collections. Five days
fter the 1st dose, the volunteer returned to deliver the feces sam-
le and to provide a blood sample of 2 ml,  for a liver enzyme test
ALT).
Before the second and the third doses, a blood sample of 5 ml  was
ollected for rotavirus serology. Again, after vaccination, the volun-
eer was observed for 2 h, being released afterwards if no adverse
vent occurred. Five days later the volunteer returned for another
lood sample collection (2 ml)  for liver toxicity, and to deliver the
eces sample. 40 days after the 3rd dose the volunteer returned for
he last blood sample collection (10 ml)  for rotavirus serology.
During the whole period of the follow-up, one of the project’s
nvestigators was available 24 h a day, should volunteers need med-
cal evaluation related to the study procedures.1 (2013) 1100– 1105 1101
2.2. Study population
79 healthy adult volunteers from 18 to 40 years of age were
selected at the Clinical Research Unit of Instituto da Crianc¸ a
(Children’s Institute) of USP’s Medical School’s Hospital (ICr-HC-
FMUSP). A call for volunteers was published in the websites of
the USP Medical School, and USP Hospital. Posters were put up
in several places within USP’s medical campus. Participants were
screened for eligibility and enrolled by the investigators following
the signing of an informed consent. Due to a recommendation from
ANVISA, female volunteers were not allowed to be recruited.
2.3. Inclusion criteria
General good health at the moment of enrollment; age from
18 to 40 years old; not using immunossupressant drugs; no clin-
ical history of gastrointestinal diseases or surgeries; no history
of cardiac, neurologic, immunologic or endocrine diseases; nor-
mal  results from the following laboratory tests: complete blood
count; glucose; liver and kidney function; urine, and also a negative
HIV serology; willing to participate and sign the Informed Consent
Form; and no participation in another clinical trial in the previous
6 months.
2.4. Exclusion criteria
To have received any other vaccine in the past 6 months.
2.5. Endpoints
The primary safety endpoint was  the presence of any solicited or
reported systemic adverse event (such as fever >37.8 ◦C, diarrhea,
vomiting, abdominal pain, post-vaccine hepatitis) or any other
adverse events (AE) observed by the investigators within the ﬁrst
ﬁve days post-vaccination. Symptoms were graded as follow: none;
mild, if they did not interfere with normal daily activities; moder-
ate, if they interfered with normal daily activities; and severe, if
participants could not perform daily activities and/or they needed
medical attention. A safety monitoring board evaluated reported
AEs throughout the entire study period.
The secondary endpoint was the vaccine’s immunogenicity. It
was  evaluated by the titers of anti-rotavirus IgA and the presence
of neutralizing antibodies anti-rotavirus. Pre-vaccination levels of
anti-rotavirus antibodies were not considered as an exclusion cri-
terion. Immunogenicity evaluation was  based on the increase of
titers. Seroconversion was  considered as a fourfold increase in IgA
titers [15,16]. The proportion of seroconverters in both groups was
compared.
2.6. Vaccine
The 5-valent rotavirus vaccine produced by the Instituto Butan-
tan is a live attenuated viral vaccine which includes ﬁve viral
antigens (G1, G2, G3, G4 and G9). It is prepared from viral suspen-
sions obtained from Vero Cells infected separately with each one
of the virus strains MVS-BRV-1 (G1), MVS-BRV-2 (G2), MVS-BRS-3
(G3), MVS-BRS-4 (G4) and MVS-BRS-10 (G9), that came from the
“Master Seed” of the US’s National Institute of Health. The strains
used to produce the pantavalent vaccine were generated from ﬁve
different human-bovine reassortants, each one containing a single
VP7-encoding gene derived from human rotavirus and 10 genes
from the bovine UK rotavirus strain [17,18].
The vaccine was produced under the WHO  Guidelines. A
working seed virus bank was  established. Vero cells from ATCC
(American Type Cell Collection) were sub-cultivated and seed
1102 E.J.A. Luna et al. / Vaccine 31 (2013) 1100– 1105
Table 1
Summary of the control tests undertaken on the Working Virus Seed (WVS) banks.
Tests Method
Bacteria and fungi Direct inoculation
Mycoplasmas Agar-cultivable
PCR
Adventitious Agents Cells cultures (3 lineages)
Animals (suckling and adult mice)
Haemadsorbing viruses Cells cultures (3 lineages)
TB  (Mycobacterium spp) “in vivo” (guinea pig)
Retrovirus RT-PCR. PERT analysis
Identity/Genetic Genotyping – Multiplex PCR
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Table 2
Summary of control tests undertaken on the Master Vero Cell bank.
Vero Master Cell bank characterization
Sterility Sterility, USP 27
Bacteriostasis/Fungistasis Direct Inoculation
Method
Mycoplasma: Points To Consider Testing for the
Presence of Agar-Cultivable and Non-Cultivable
Mycoplasma
Viruses General Tissue Culture Safety Testing: 28 day In vitro assay
using MRC-5, Vero and Primary AGMK as indicator
cell lines. Observation for both CPE and
hemadsorption.
General Detection of Inapparent Viruses by Inoculation of a
Test Article into Guinea Pigs, Mice (weanling and
suckling) and Embryonated Chicken Eggs (In Vivo)
General Ultrastructural Evaluation of Cell Cultures for Viral
Particles, with Characterization and Tabulation of
Retrovirus-like Particles by TEM
Bovine In vitro Test for Bovine Adventitious Viral Agents
in  Products Other Than Bovine Serum: Modiﬁed
9CFR (9 Virus Panel)
Porcine Test for Porcine Adventitious Viral Agents (8 Virus
Panel)
Human Detection and Quantitation of Human
Cytomegalovirus (CMV) in Biological Samples
using PCR with Fluorescent Dye-Labeled Probes
and Fluorescence Detection of Ampliﬁcation
Human Detection and Quantitation of Human
Immunodeﬁciency Virus (HIV) Sequences in
Biological Samples using PCR with Fluorescent
Dye-Labeled Probes and Fluorescence Detection of
Ampliﬁcation
Human Detection and Quantitation of Human T-Cell
Lymphotropic Virus (HTLV) sequences in Biological
Samples Using PCR with Fluorescent Dye-Labeled
Probes and Fluorescence Detection of
Ampliﬁcation
Human Detection of Epstein Barr Virus (EBV), Types 1 & 2,
in Biological Samples Using Polymerase Chain
Reaction
Human Hepatitis A, B & C
General Retrovirus PCR- Based Reverse Transcriptase Assay (PBRT)
Using Fluorescence Detection of Ampliﬁcation
Simian Detection and Quantiﬁcation of Simian
T-Lymphotropic Virus (STLV) Sequences in
Biological Samples Using PCR with Fluorescent
Dye-Labeled Probes and Fluorescence Detection of
Ampliﬁcation
Simian Detection and Quantiﬁcation of Simian
Immunodeﬁciency Virus (SIV) Sequences in
Biological Samples Using PCR with Fluorescent
Dye-Labeled Probes and Fluorescence Detection of
Ampliﬁcation
Simian Detection and Quantiﬁcation of Simian Foamy
Virus (SFV) Sequences in Biological Samples Using
PCR with Fluorescent Dye-Labeled Probes and
Fluorescence Detection of Ampliﬁcation
Simian Detection and Quantiﬁcation of Simian Virus 40
(SV40) Sequences in Biological Samples Using PCR
with Fluorescent Dye-Labeled Probes and
Fluorescence Detection of Ampliﬁcation
Simian Detection and Quantiﬁcation of Simian Retrovirus
(SRV) Sequences in Biological Samples Using PCR
with Fluorescent Dye-Labeled Probes and
Fluorescence Detection of Ampliﬁcation
2.9. Rotavirus detection in fecessequences Sequence – Big Dye Terminator
Titration for infectivity PFA (Plaque Forming Assay)
ells and working cell banks were established. Cell banks under-
ent quality control tests recommended by the WHO  Guidelines
19]. The working virus seed (WVS) were prepared with rotavirus
uspensions obtained of Vero cell cultures infected with virus
trains from master virus seed (NIH) and maintained in serum free
edium. The master virus seed banks from NIH were approved
n the following control tests: sterility, mycoplasma, adventitious
gents in vitro (TB, Tests for BVDV, bovine virus detection, BIV, BLV,
PyV, porcine virus, MAP  test with LCM challenge), agents adven-
itious “in vivo” (animals and embryonated eggs), for retroviruses
RT-PCR and PERT) and virus potency. Table 1 summarizes the qual-
ty control tests undertaken on the WVS. Control tests on the Master
ell Bank are summarized in Table 2.
Samples of the monovalent rotavirus vaccines and of the pen-
avalent formulation were tested for the absence of bacteria, fungi,
ycoplasmas, adventitious agents, mycobacterium, retroviruses,
aemadsorbing viruses, as well as identity/genetic sequences and
ritation for infectivity (potency).
In the vaccine formulation, rotavirus suspensions obtained from
nfected Vero cells were mixed to ensure similar concentration of
he ﬁve serotypes. Each dose of the vaccine contained approxi-
ately 1 × 106 PFU, with 105–105.5 PFU of each serotype. A speciﬁc
accine lot was used in the trial (Lot 209). The vaccine was  stored
etween 2 and 8 ◦C. Viral suspensions were diluted in a buffer
olution (Eagle medium, sucrose, potassium phosphates, mono-
odium glutamic acid and sodium bicarbonate). The lyophilized
accine was reconstituted with a citrate-phosphate buffer to neu-
ralize the mouth’s acid pH. After formulation, the vaccine passed
he following quality control tests: potency, pH, identity, presence
f serotypes, sterility and accelerated stability.
.7. Placebo
The placebo was manufactured separately from the vaccine. It
as formed by the supernatants of Vero cell cultures not infected
y rotavirus, diluted in the same concentration and with the same
omponents used in the vaccine preparation. The placebo had the
ame volume, color and taste as the vaccine. It was tested for steril-
ty, mycoplasma, adventitious agents, pH, residual moisture and
ndotoxins.
.8. Detection of rotavirus antibodies in paired serum samples
Antibody responses were evaluated in a fourfold or greater
ncrease in serum rotavirus-speciﬁc IgA ELISA or plaque reduction
eutralization assay (PRNT) [15,20] to G1, G2, G3, G4, G9 and “UK”.
he former ﬁve correspond to the VP7 antigens, speciﬁc for each
train, and the latter one corresponding to the antibodies to VP4
ntigen, common to all ﬁve strains. The pre- and post-dose serum
amples from the each volunteer were tested in the same serotypeIdentity Isoenzyme and Cytogenetic Analysis
Tumor Formation Tumorigenicity in Nude Mice
speciﬁc assay. All rotavirus laboratory analyses were undertaken by
the Instituto Adolfo Lutz, São Paulo State Public Health Laboratory.The viral shedding was  examined in stool samples collected after
the ﬁrst and third doses of the vaccine or placebo. The samples
cine 31 (2013) 1100– 1105 1103
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Assessed for eligibility
(n=98)
Randomized
(n=80)
Allocated to 
intervenon group
(n = 40) 
Completed follow up
(n=39)
Allocated to control 
group
(n = 40)
 Completed follow up
(n=40)
Excluded (n=18):
Refusal (n= 3)
Screening failure (n = 15) 
T
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ere tested for rotavirus antigen by enzyme immunoassay (EIA),
sing a commercial kit (Primier ROTACLONE® – Meridian Diag-
ostic, Inc.), and reverse-transcriptase-polymerase-chain-reaction
RT-PCR). Rotavirus G and P genotyping were identiﬁed by PCR.
21,22]
.10. Data analysis
As in most phase I trials, sample size was not calculated to
rovide statistically signiﬁcant differences between groups. Rather,
 descriptive analysis on the frequency of AE and immunogenic-
ty data was undertaken. When deemed appropriate, statistical
ests were used. Continuous variables were compared between
he two groups using Student’s t test and Wilcoxon rank-sum
est, and categorical data using chi-square and Fisher exact test.
xact 95% conﬁdence intervals were calculated for the propor-
ions of seroconversion. All statistical analyses were performed in
 blinded way. Softwares EpiInfo version 3.5.1 (CDC, 2006, Atlanta,
A) and Stata version 9.0 (StataCorp. 2005. Stata Statistical Soft-
are: Release 9. College Station, TX) were used in the analysis.
. Results
98 potential volunteers were interviewed, 80 of them were
nrolled (Fig. 1), and 79 completed the follow-up. All volunteers
ere male, with a median age of 28 years (30 years in the experi-
ental group and 27 in the control group, p = 0.48). There were no
ifferences in baseline characteristics, such as race/ethnicity and
chooling level, between experimental and control groups (data
ot shown). One volunteer of the experimental group was excluded
rom the follow-up because of protocol violation.
.1. Safety
Complaints and solicited symptoms were investigated follow-
ng the ﬁrst ﬁve days after vaccination (Table 3). No severe adverse
vents were reported. None of the volunteers sought out the
esearch unit for any adverse event. Only two volunteers needed
edical appointments during the follow up, for reasons apparently
ot related to the trial: one had pneumonia and the other one,
 sporting injury. Of the 51 complaints and symptoms referred,
3% were gastrointestinal symptoms. Eight volunteers reported
able 3
requency and proportion of complaints and solicited symptoms during the 5-day period
Complaint/symptom 1st dose 2
Vaccine n = 39 Placebo n = 40 V
Headache 3 (7.7%) 2 (5.0%) 
Fever  1 (2.6%) 0 (0.0%) 
Flu-like  symptoms 1 (2.6%) 2 (5.0%) 
Gastrointestinal symptoms a 5(12.8%)a 7c
Diarrhea 1 (2.6%) 3 (7.5%) 
Nausea/Vomiting 1 (2.6%) 0 (0.0%) 
Loss  of appetite 2 (5.1%) 0 (0.0%) 
Malaise 1 (2.6%) 0 (0.0%) 
Loose  stools 0 (0.0%) 2 (5.0%) 
Abdominal pain 0 (0.0%) 1 (2.5%) 
Increased defecation frequency 0 (0.0%) 1 (2.5%) 
Dyspepsia 0 (0.0%) 0 (0.0%) 
Otherb 4 (10.3%) 1 (2.5%) 
Total  14 (35.9%) 12 (30.0%) 
a Corresponds to the sum of the 8 lines below.
b Complaints and symptoms: orthopedic (3), dental (1), dermatologic (1).
c 2 = 0.07 p = 0.79.
d 2 = 0.43 p = 0.51.
e Fisher exact test p = 1.00.Fig. 1. Participant’s ﬂowchart.
diarrhea, two  in the vaccine group and six in the placebo group.
They reported from 3 to 10 evacuations in a 24-h interval. One
of them, in the placebo group, referred his infant son presented
diarrhea one day before him. All digestive symptoms were mild
and resolved within 24 h. There was no signiﬁcant difference in the
frequency of pooled gastrointestinal symptoms between the two
groups, after any of the doses (Table 3). Only three volunteers pre-
sented abnormal hepatic enzymes (ALT and/or AST) results, two
in the vaccine group after the third dose, and one in the placebo
group after the second dose. The increase was temporary, and levels
returned to normal within a few days.
 after vaccination, according to dose and group.
nd dose 3rd dose
accine n = 39 Placebo n = 40 Vaccine n = 39 Placebo n = 40
1 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
2 (5.1%) 3 (7.5%) 3 (7.7%) 0 (0.0%)
8d 5d 2e 3e
1 (2.6%) 1 (2.5%) 0 (0.0%) 2 (5.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.5%)
1 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
2 (5.1%) 1 (2.5%) 0 (0.0%) 0 (0.0%)
2 (5.1%) 0 (0.0%) 2 (5.1%) 0 (0.0%)
0 (0.0%) 2 (5.0%) 0 (0.0%) 0 (0.0%)
0 (0.0%) 1 (2.5%) 0 (0.0%) 0 (0.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
9 (23.1%) 8 (20.0%) 5 (12.8%) 3 (7.5%)
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Table 4
Proportion of seroconversion, deﬁned as a 4-fold increase in titers as for baseline, for the vaccine and placebo groups after the ﬁrst, second and third doses, per serotype.
Vaccine Placebo
Serotypes
G1 N % (95% CI) N % (95% CI)
Post  1st dose 39 48.7 (32.4–65.2) 40 0.0 (0.0–9.0)
Post  2nd dose 39 56.4 (39.6–72.2) 40 7.5 (1.6–20.4)
Post  3rd dose 39 61.5 (44.6–76.6) 40 12.5 (4.2–26.8)
G2
Post  1st dose 39 38.5 (23.4–55.4) 40 2.5 (0.1–13.2)
Post  2nd dose 39 43.6 (27.8–60.4) 40 7.5 (1.6–20.4)
Post  3rd dose 39 53.8 (37.2–69.9) 40 12.5 (4.2–26.8)
G3
Post  1st dose 39 43.6 (27.8–60.4) 40 0.0 (0.0–9.0)
Post  2nd dose 39 53.8 (37.2–69.9) 40 5.0 (0.6–16.9)
Post  3rd dose 39 56.4 (39.6–72.2) 40 10.0 (2.8–23.7)
G4
Post  1st dose 39 38.5 (23.4–55.4) 40 2.5 (0.1–13.2)
Post  2nd dose 39 53.8 (37.2–69.9) 40 10.0 (2.8–23.7)
Post  3rd dose 39 56.4 (39.6–72.2) 40 15.0 (5.7–29.8)
G9
Post  1st dose 39 38.5 (23.4–55.4) 40 0.0 (0.0–9.0)
Post  2nd dose 39 53.8 (37.2–69.9) 40 2.5 (0.1–13.2)
Post  3rd dose 39 56.4 (39.6–72.2) 40 7.5 (1.6–20.4)
UK
Post  1st dose 24 37.5 (18.8–59.4) 18 0.0 (0.0–18.0)
Post  2nd dose 24 58.3 (36.6–7
Post  3rd dose 24 58.3 (36.6–7
Abbreviation: CI = conﬁdence interval.
Table 5
ELISA IgA (optical density) results for the vaccine and placebo groups after the ﬁrst,
second and third doses.
Vaccinated n = 39 Placebo n = 40 p-value
Median (IQR)
Pre-vaccinations 0.40 (0.29–0.63) 0.38 (0.27–0.64) 0.38
Post  1st dose 0.57 (0.44–0.80) 0.36 (0.29–0.43) <0.001
Post 2nd dose 0.51 (0.43–0.73) 0.37 (0.28–0.43) <0.001
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aPost 3rd dose 0.51 (0.41–0.71) 0.30 (0.35–0.46) <0.001
bbreviations: IQR = interquartile range.
.2. Immunogenicity
The proportion of seroconversion was larger in the vaccine
roup (Table 4), after each dose and for all ﬁve serotypes. Anti-
ody levels were signiﬁcantly higher in the vaccine group after the
accination in comparison to the placebo group (Table 5).
.3. Viral shedding
No viral shedding was detected, either after the ﬁrst dose or after
he third dose of the vaccine or placebo, in fecal samples from the
olunteers (data not shown).
. Discussion
This phase I trial of an orally administered 5-valent attenu-
ted rotavirus vaccine, conducted in a sample of healthy adult
olunteers, has provided evidence on the vaccine’s safety and
mmunogenicity. No severe adverse events were observed. There
as no signiﬁcant difference in the frequency of AE between
xperimental and control groups after any doses. Mild episodes of
iarrhea were more frequent in the control group. Transient rise
n hepatic enzymes was observed in three volunteers. Apparently
here was no replication of the vaccine virus in the intestinal tract
ince no viral excretion was detected.
Although the primary objective of this trial was to gather data on
he vaccine’s safety, evidence of the vaccine’s immunogenicity was
lso obtained. The proportion of seroconversion was  consistently7.9) 18 5.6 (0.1–27.3)
7.9) 18 5.6 (0.1–27.3)
higher in the vaccine group, for all serotypes in all measurements,
after each one of the doses. A quadrivalent formulation containing
4 of the serotypes included in the vaccine (G1, G2, G3 and G4)  had
already been submitted to phase I trials, presenting a promising
safety and immunogenicity proﬁle in adults, children and infant
samples [15,20,23].  In our trial, the proportion of seroconversion
was  higher than in the previous phase I trial among adults. Some of
the volunteers in the control group also presented seroconversion
to one or more serotypes during the follow-up. This ﬁnding prob-
ably suggests that rotavirus circulate among the adult population
from which the sample was recruited. However, the proportion of
seroconversion was  signiﬁcantly higher in the vaccine group, for all
serotypes in all measures after each one of the doses.
The present trial adds evidence of safety and immunogenicity
of the UK based reassortant rotavirus vaccines. Despite the small
sample size, the vaccine safety and immunogenicity have been
demonstrated in this sample of adult volunteers. These results are
encouraging. The vaccine candidate needs to be evaluated further
in larger trials, among the target population.
Acknowledgement
This study was  funded by Butantan Foundation, with grants
from BNDES (Project no.115/08).
EJA Luna is employee of the Instituto de Medicina Tropical,
Universidade de São Paulo. He has received research grants from
Butantan Foundation. NM Frazatti-Gallina, JL Miraglia, I Raw and AR
Precioso are employees of Instituto Butantan. MCST Timenetsky is
employee of Instituto Adolfo Lutz. MRA  Cardoso is employee of the
Departamento de Epidemiologia, Faculdade de Saúde Pública, Uni-
versidade de São Paulo. MASM Veras is employee of Faculdade de
Ciências Médicas da Santa Casa de São Paulo. AMU  Escobar and SJFE
Grisi are employees of the Departamento de Pediatria, Faculdade
de Medicina, Universidade de São Paulo.We  thank the subjects who volunteered for the study, and also
the following colleagues who  contributed to the study: Dr. Hisako
Higashi, Dr. Alfredo Giglio, Dr. Tania Vaz, Dr. Norma Santos, Dr. José
Cássio de Moraes, Ms.  Audrey Cilli, Dr. Ricardo Albernaz, Dr. Ivone
cine 3
Y
M
R
[
[
[
[
[
[
[
[
[
[
[
[
[E.J.A. Luna et al. / Vac
amaguchi, Ms.  Cláudia Koike, Ms.  Carolina Gill, Ms.  Rosana L. Paoli,
r.  Luís F. Oliveira and Ms.  Simone Santos.
eferences
[1] Chandran A, Fitzwater S, Zhen A, Santosham M.  Prevention of rotavirus gas-
troenteritis in infants and children: rotavirus vaccine safety, efﬁcacy, and
potential impact of vaccines. Biologics 2010;4:213–29.
[2]  Patel M,  Pedreira C, De Oliveira LH, Tate J, Orozco M,  Mercado J, et al. Association
between pentavalent rotavirus vaccine and severe rotavirus diarrhea among
children in Nicaragua. JAMA 2009;301(June (21)):2243–51.
[3] Richardson V, Hernandez-Pichardo J, Quintanar-Solares M,  Esparza-Aguilar M,
Johnson B, Gomez-Altamirano CM, et al. Effect of rotavirus vaccination on
death from childhood diarrhea in Mexico. N Engl J Med  2010;362(January
(4)):299–305.
[4] do Carmo GM,  Yen C, Cortes J, Siqueira AA, de Oliveira WK,  Cortez-Escalante
JJ,  et al. Decline in diarrhea mortality and admissions after routine childhood
rotavirus immunization in Brazil: a time-series analysis. PLoS Med 2011;8(April
(4)):e1001024.
[5]  Meeting of the immunization Strategic Advisory Group of Experts, April 2009
– conclusions and recommendations. Wkly Epidemiol Rec 2009; 84 June
(23):220–36.
[6] Ward RL, McNeal MM,  Steele AD. Why  does the world need another rotavirus
vaccine? Ther Clin Risk Manag 2008;4(February (1)):49–63.
[7] Parashar UD, Glass RI. Public health. Progress toward rotavirus vaccines. Science
2006;312(May (5775)):851–2.
[8] Timenetsky MCST, Carmona RCC, Morillo SG, Eduardo MBPE, Silva LJ. Incidence
of  rotavirus G and P genotypes in children in southern Brazil. Emergence of
genotype G9. [abstract V-330]. In: Abstracts of the International Congress of
Virology, Joint Meeting of the 3 Divisions of the International Union of Micro-
biological Societies; San Francisco, 2005 July 23–28. International Union of
Microbiological Societies; 2005.
[9]  Nakagomi T, Cuevas LE, Gurgel RG, Elrokhsi SH, Belkhir YA, Abugalia M,
et  al. Apparent extinction of non-G2 rotavirus strains from circulation
in  Recife, Brazil, after the introduction of rotavirus vaccine. Arch Virol
2008;153(3):591–3.
10] Carvalho-Costa FA, Volotao Ede M, de Assis RM,  Fialho AM,  de Andrade J, da
S,  et al. Laboratory-based rotavirus surveillance during the introduction of a
vaccination program, Brazil, 2005–2009. Pediatr Infect Dis J 2011;30(January
(1  Suppl.)):S35–41.
11] Gomez MM,  de Mendonca MC,  Volotao Ede M,  Tort LF, da Silva MF,  Cristina
J,  et al. Rotavirus A genotype P[4] G2: genetic diversity and reassortment
[1 (2013) 1100– 1105 1105
events among strains circulating in Brazil between 2005 and 2009. J Med  Virol
2011;83(June (6)):1093–106.
12] Ruiz-Palacios GM,  Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens
SC,  et al. Safety and efﬁcacy of an attenuated vaccine against severe rotavirus
gastroenteritis. N Engl J Med  2006;354(January (1)):11–22.
13] Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M,  Rodriguez
Z,  et al. Safety and efﬁcacy of a pentavalent human-bovine (WC3) reassortant
rotavirus vaccine. N Engl J Med  2006;354(January (1)):23–33.
14] Patel MM,  Lopez-Collada VR, Bulhoes MM,  De Oliveira LH, Bautista Mar-
quez A, Flannery B, et al. Intussusception risk and health beneﬁts of
rotavirus vaccination in Mexico and Brazil. N Engl J Med  2011;364(June (24)):
2283–92.
15] Clements-Mann ML,  Makhene MK,  Mrukowicz J, Wright PF, Hoshino Y, Midthun
K,  et al. Safety and immunogenicity of live attenuated human-bovine (UK)
reassortant rotavirus vaccines with VP7-speciﬁcity for serotypes 1, 2, 3 or 4
in  adults, children and infants. Vaccine 1999;17(June (20–21)):2715–25.
16] Soares-Weiser K, MacLehose H, Ben-Aharon I, Goldberg E, Pitan F, Cunlife N.
Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review). Cochrane
Database Syst Rev 2010;May (6):1–188.
17] Hoshino Y, Jones RJ, Chanock RM,  Kapikian AZ. Construction of four double gene
substitution human × bovine rotavirus reassortant vaccine candidates. J Med
Virol 1997;51:319–25.
18] Hoshino Y, Jones RW,  Ross J, Honma S, Santos N, Gentsch JR, et al. Rotavirus
serotype G9 strains belonging to VP7 gene phylogenetic sequence lineage 1
may  be more sutiable for serotype G9 vaccine candidates than those belonging
to lineage 2 or 3. J Virol 2004;78(July (14)):7795–802.
19] World Health Organization. Annex 3: Guidelines to assure the quality, safety
and efﬁcacy of live attenuated rotavirus vaccines (oral). Technical Report Series
no.  941; 2007.
20] Clements-Mann ML,  Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M,  et al.
Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK)
reassortant rotavirus vaccine administered with childhood vaccines to infants.
Vaccine 2001;19(September (32)):4676–84.
21] Gouvea V, Glass RI, Woods P, Taniguchi K, Clark HF, Forrester B, et al. Polymerase
chain reaction ampliﬁcation and typing of rotavirus nucleic acid from stool
specimens. J Clin Microbiol 1990;28:276–82.
22] Gentsch JR, Glass RI, Woods P, Gouvea V, Gorziglia M, Flores J, et al. Identiﬁcation
of  group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol
1992;30:1365–73.
23] Eichelberger MC,  Sperber E, Wagner M, Hoshino Y, Dudas R, Hodgins V, et al.
Clinical evaluation of a single oral dose of human-bovine (UK) reassortant
rotavirus vaccines Wa  × UK (P1A[8],G6) and Wa × (DS-1 × UK)  (P1A[8],G2). J
Med  Virol 2002;66(March (3)):407–16.
